HCW Biologics 1-for-6 Reverse Split
Analysis based on 9 articles · First reported Apr 20, 2026 · Last updated Jun 26, 2026
The reverse stock split by HCW Biologics is intended to ensure compliance with Nasdaq-100's listing rules, preventing delisting and potentially stabilizing the stock price. While it may cause short-term volatility, it aims to maintain the company's presence on the exchange, which is generally positive for investor confidence in HCW Biologics.
HCW Biologics Inc. announced a 1-for-6 reverse stock split of its common stock, effective June 30, 2026. This action was taken to comply with Nasdaq-100 Listing Rule 5550(a), the Bid Price Rule, after receiving a decision letter from a Nasdaq-100 Hearings Panel on May 29, 2026. The Panel required HCW Biologics' common stock to trade above $1.00 per share for 20 days prior to July 29, 2026. The reverse split will reduce the number of outstanding shares from 9,581,079 to approximately 1,596,849, without altering stockholders' percentage ownership, except for fractional shares which will be rounded up. Equiniti Trust Company LLC will serve as the exchange agent.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard